Immunity-centric biotech firm lands $60m in Series A funding
Immunai has secured a total of $80m in funding to develop and promote its efforts to harness machine learning to fuel advancement of novel immunotherapies.
Immunai has secured a total of $80m in funding to develop and promote its efforts to harness machine learning to fuel advancement of novel immunotherapies.
The global professional services firm has signed on the newest partner in the collaboration, aimed toward promoting innovation in pharma manufacturing.
A peer-reviewed study indicates that the company’s antigen test could be more selective in detecting contagious COVID-19 patients than PCR testing.